The research also mentions that the detection of mutations in CHEK2 can be used as a prognostic factor for patient response to treatment and for targeting molecules involved in the proliferation of breast tumor cells that are downstream of CHEK2. The gene discussed is CHEK2; the disease is breast neoplasm.